OncoCyte (NYSE:OCX) Receives New Coverage from Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of OncoCyte (NYSE:OCX – Get Free Report) in a research report issued on Friday. The brokerage set a “sell” rating on the stock.

OncoCyte Stock Down 1.8 %

Shares of OCX opened at $0.22 on Friday. OncoCyte has a 12 month low of $0.20 and a 12 month high of $1.10.

Get OncoCyte alerts:

OncoCyte Company Profile

(Get Free Report)

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.

See Also

• Five stocks we like better than OncoCyte
• Delta Takes Flight: Double-Digit Upside In Sight
• Generac Powers Up as Summer Temperatures Rise
• 3 Reasons Why Rivian Can Continue To Surge Higher
• Despite Breaking Higher, Analysts Remain Cautious HP Inc.
• PepsiCo Can Soar To New Highs In The 2nd Half

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.